** Shares of diabetes device makers fall between 1% to 3% before the bell
** Eli Lilly LLY.N says its oral drug orforglipron led to an average weight loss of 7.9% and lowered blood sugar for overweight patients with type 2 diabetes in a late-stage trial
** Shares of Dexcom DXCM.O, which manufactures continuous glucose monitors, down 2.6% at $66.94 premarket
** Shares of insulin pump makers Tandem Diabetes Care TNDM.O and Insulet Corp PODD.O down around 2% each
** LLY shares rise 13.4% to $833.56 premarket
** As of last close, DXCM down 11.6%, TNDM down 52.1%, LLY down 4.8%, PODD down 4% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.